New combo aims to boost transplant success in tough lymphoma

NCT ID NCT07451652

Recruiting now Disease control Sponsor: Hospital Universitario Dr. Jose E. Gonzalez Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a combination of two chemotherapy drugs (gemcitabine and oxaliplatin) plus a low dose of the immunotherapy epcoritamab in 10 people whose diffuse large B-cell lymphoma has come back or not responded to prior treatment. Participants must be eligible for a stem cell transplant. The goal is to see if this approach improves response rates and is safe enough to avoid hospitalization during the first treatment cycle.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma relapsed/refractory diffuse large B-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Hospital Universitario "Dr. José Eleuterio González"
RECRUITING

Monterrey, Nuevo León, 64640, Mexico